surmount-1 tirzepatide weight loss percent 72 weeks Analysis of Acquisition Costs and Reduction Outcomes in the United Kingdom: Insights from the Study | Advances in Therapy SURMOUNT-1 Trial - Cardionerds Twitter

Reduced caloric intake can contribute, especially if the appetite suppression leads to unintentionally skipping meals

While we do not prescribe medications directly, we can guide you on the right questions to ask your healthcare provider

Missed doses and timing flexibility Real life does not always cooperate with weekly injection schedules

State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval

Are there other treatments being investigated